

May 01, 2024

**National Stock Exchange of India Limited**  
Plot No. C/1, "G" Block, Exchange Plaza,  
Bandra Kurla Complex, Bandra (East),  
Mumbai 400 051

**BSE Limited**  
Phiroze Jeejeebhoy Towers,  
Dalal Street,  
Mumbai 400 001

**Symbol: RPGLIFE**

**Security Code: 532983**

Dear Sirs /Madam,

**Sub: Regulation 30 read with Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015**

In terms of the Regulation 30 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith a copy of the newspaper publications with respect to Audited Financial Results for the quarter and year ended March 31, 2024.


Kindly take this information on record.

Thanking you,

Yours Sincerely,  
For RPG Life Sciences Limited

RAJESH RAMESH  
SHIRAMBEKAR  
Rajesh Shirambekar  
Head – Legal & Company Secretary

Digitally signed by RAJESH  
RAMESH SHIRAMBEKAR  
Date: 2024.05.01 22:12:55 +05'30'



Encl. as above



## RPG LIFE SCIENCES LIMITED

Regd. Office: RPG House, 463, Dr. Annie Besant Road, Worli, Mumbai -400 030.  
CIN: L24232MH2007PLC169354;  
Tel: +91-22-6975 7100;  
E-mail: info@rpglifesciences.com; Web: www.rpglifesciences.com

### Extract of Standalone Audited Financial Results for the Quarter and Year ended March 31, 2024

Particulars	(Rs. in Lakhs)			
	Quarter ended		Year ended	
	March 31, 2024 (Audited)	March 31, 2023 (Audited)	March 31, 2024 (Audited)	March 31, 2023 (Audited)
1 Total Income from Operations	12,864	12,033	58,926	51,761
2 Net Profit for the period (before tax, exceptional and extraordinary items)	1,774	1,381	11,784	9,168
3 Net Profit for the period before tax (after exceptional and extraordinary items)	1,774	1,381	11,784	9,168
4 Net Profit for the period after tax (after exceptional and extraordinary items)	1,324	1,035	8,786	6,764
5 Total Comprehensive Income for the period [Comprising Profit for the period (after tax) and Other Comprehensive Income (after tax)]	1,264	1,062	8,710	6,771
6 Paid-up equity share capital (Face Value Rs. 8/- each)	1,323	1,323	1,323	1,323
7 Reserves (excluding Revaluation Reserve) as shown in the Audited Balance sheet of the previous year	-	-	36,162	29,437
8 Earnings Per Share (Rs. 8/- each) - (not annualised for quarter):				
Basic (in Rs.)	8.01	6.26	53.01	40.90
Diluted (in Rs.)	8.01	6.26	53.01	40.90

#### Notes:

- The above results have been reviewed by the Audit Committee at its meeting held on April 29, 2024 and approved by the Board of Directors at its meeting held on April 30, 2024.
- The Company operates in only one reportable business segment i.e. Pharmaceuticals.
- Figures of the quarter ended March 31, 2024 and March 31, 2023 are the balancing figure between audited figures in respect of the full financial year and the year to date figures upto the third quarter of the relevant financial year which were subjected to limited review by Auditors.
- The Board of Directors has recommended a final dividend of Rs. 16/- (Rupees Sixteen only) per equity share (200% on the face value of Rs. 8 each) for the financial year 2023-24, subject to the approval of shareholders at the ensuing Annual General Meeting.
- The above is an extract of the detailed format of Quarterly Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the Quarterly Financial Results is available on Stock Exchange websites viz. [www.nseindia.com](http://www.nseindia.com) and [www.bseindia.com](http://www.bseindia.com) and on Company's website ([www.rpglifesciences.com](http://www.rpglifesciences.com)).

For RPG Life Sciences Limited

Place : Mumbai  
Date : April 30, 2024

Yugal Sikri  
Managing Director  
DIN: 07576560

